For­get TIG­IT: No­var­tis’ $1B bet on BeiGene’s ociper­limab ends af­ter com­peti­tors’ set­backs

Last year
Deals
R&D

BAKX Ther­a­peu­tics to shut down af­ter ‘sci­en­tif­ic chal­lenges’ and fi­nanc­ing dol­drums

Last year
People
Startups

Ex­clu­sive: Brig­gs Mor­rison's Cross­bow Ther­a­peu­tics nabs $80M from MPM, Pfiz­er Ven­tures, Lil­ly in hunt for bet­ter ...

Last year
Financing
Startups

Ex­clu­sive: Pfiz­er to in­vest $25M in­to tiny UK biotech with epi­ge­net­ics ap­proach to can­cer

Last year
Financing
Deals

Septer­na’s $150M in­fu­sion will help prove whether it’s got the right pill for hy­poparathy­roidism

Last year
Financing
Startups

Ei­sai’s US chair, glob­al Alzheimer’s leader to re­tire weeks af­ter Leqem­bi ap­proval

Last year
People

Tes­sa en­joyed big back­ers, great sci­ence and world-class am­bi­tion. So what did we learn from its col­lapse?

Last year
Bioregnum
Cell/Gene Tx

Astel­las eyes rare oph­thal­mol­o­gy, li­cens­ing 4DMT's vi­ral vec­tor for gene ther­a­py for up to $962M

Last year
Deals
Cell/Gene Tx

No­var­tis faces one win, one loss in patent cas­es over block­buster heart fail­ure drug

Last year
Pharma
Law

Virid­i­an tar­gets Hori­zon's Te­pez­za with chron­ic thy­roid eye dis­ease da­ta, set­ting up the biotech for its sec­ond PhI­II

Last year
R&D

Avadel launch­es quick start to nar­colep­sy drug’s mar­ket­ing af­ter long road to ap­proval

Last year
Pharma
Marketing

Bernie Sanders wants HHS to look in­to the price of Ei­sai's new­ly ap­proved Alzheimer's drug

Last year
Pharma
Law

Melin­ta se­cures $142M BAR­DA deal to tar­get pe­di­atric and 'bio­threat' in­di­ca­tions for an­tibi­otics

Last year
Deals
Pharma

No­var­tis and Sam­sung ink five-year, $309M ex­pan­sion to bi­o­log­ics man­u­fac­tur­ing part­ner­ship

Last year
Manufacturing

Up­dat­ed: Eu­ro­pean reg­u­la­tors in­ves­ti­gat­ing 150 re­ports of self-in­jury, sui­cide risk in pa­tients tak­ing No­vo Nordisk ...

Last year
Pharma
Marketing

Mer­ck and Mod­er­na to start piv­otal can­cer vac­cine tri­al

Last year
R&D

Ful­crum inks dis­cov­ery deal with Camp4 Ther­a­peu­tics

Last year
Deals

BeiGene fur­ther in­vests in AD­Cs with sol­id tu­mor part­ner Du­al­i­ty­Bio, a BioN­Tech col­lab­o­ra­tor

Last year
Startups
Deals

Apogee and Sagimet’s IPO plans come in­to view, with tar­get­ed rais­es of $228M and $66M

Last year
Financing
Startups

Kris­ten Hege re­flects on the birth of CAR-T re­search as she reach­es the 'end of the be­gin­ning' of her PCT thru-hike

Last year
Biotech Voices

WuXi Bi­o­log­ics seeks spin­out, HK list­ing of bio­con­ju­gates-fo­cused joint ven­ture

Last year
Financing
China

A year af­ter cost cuts, Nanobi­otix has a deal with J&J to li­cense its lead ra­dioen­hancer prod­uct

Last year
Deals

Alzheimer’s drug Leqem­bi gets full OK; Biotech’s H1 by the num­bers; Bring­ing Leerink back; Against AI over­hype; ...

Last year
Weekly

Pfiz­er adds shifts, in­vests re­sources to cope with surge in de­mand for syphilis treat­ment

Last year
Pharma
Manufacturing
First page Previous page 314315316317318319320 Next page Last page
A service from the Financial Times